Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 14/20 | 0.54 |
| ▸ | FNTB | P49356 | 13/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20657039 | 1.00 | FNTA (0.54) | FNTAFNTBALDH1A1MAPTPGGT1B | |
| SCHEMBL28193348 | 1.00 | FNTA (0.54) | FNTAFNTBALDH1A1MAPTPGGT1B | |
| SCHEMBL1529433 | 1.00 | FNTA (0.54) | FNTAFNTBALDH1A1MAPTPGGT1B | |
| SCHEMBL359894 | 1.00 | FNTA (0.54) | FNTAFNTBALDH1A1MAPTPGGT1B | |
| SCHEMBL28784346 | 1.00 | FNTA (0.54) | FNTAFNTBALDH1A1MAPTPGGT1B | |
| SCHEMBL1820771 | 1.00 | FNTA (0.54) | FNTAFNTBALDH1A1MAPTPGGT1B | |
| SCHEMBL359893 | 1.00 | FNTA (0.54) | FNTAFNTBALDH1A1MAPTPGGT1B | |
| SCHEMBL20535484 | 1.00 | FNTA (0.54) | FNTAFNTBALDH1A1MAPTPGGT1B | |
| SCHEMBL11856516 | 0.98 | FNTA (0.51) | FNTAFNTBALDH1A1MAPT | |
| SCHEMBL3860439 | 0.98 | FNTA (0.51) | FNTAFNTBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009108713-A2 | TOPICAL COMPOSITIONS AND METHODS UTILIZING PEPTIDES CONTAINING LIPID-MODIFIED CYSTEINE-CONTAINING PEPTIDES | SIGNUM BIOSCIENCES, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| US-20090155186-A1 | Compositions and methods for treating inflammatory conditions | SIGNUM BIOSCENCES, INC. (NJ) | 2009-06-18 | — | — | US | disclosed |
| EP-1899480-A4 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNUM BIOSCIENCES INC (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1899480-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNUM BIOSCIENCES, INC. (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006135894-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNUM BIOSCIENCES, INC. (US) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155186-A1 | Compositions and methods for treating inflammatory conditions | TNF, TRAF6, RELA | FNTA 1480/4885FNTB 2976/4885ALDH1A1 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.